In contrast, erlotinib, an EGFR tyrosine kinase inhibitor (TKI), combined with cisplatin-based concurrent chemoradiation (E+CRT) demonstrated notable efficacy in locally advanced CC (170). The gene discussed is EGFR; the disease is cholangiocarcinoma.